Low Expression of PRRG2 in Kidney Renal Clear Cell Carcinoma: an Immune Infiltration-associated Prognostic Biomarker

Overview

Journal Discov Oncol

Publisher Springer

Specialty Oncology

Date 2024 Jan 16

PMID 38227081

Authors

Gonglin Tang

Guixin Ding

Gang Wu

Xiaofeng Wang

Tianqi Wang

Qingsong Zou

Kai Sun

Jitao Wu

Affiliations

Soon will be listed here.

Abstract

Objective: This study aims to explore the prognostic significance of Proline-rich γ-carboxyglutamic acid protein 2 (PRRG2) in Kidney Renal Clear Cell Carcinoma (KIRC), a prevalent and deadly cancer, and its association with immune cell infiltration, a key strategy in developing effective biomarkers.

Methods: The study meticulously elucidated the prognostic significance and potential role of PRRG2 in KIRC, correlating its expression with patient sex, age, metastasis, and pathological stage. Utilizing Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Set Enrichment Analysis (GSEA), the involvement of PRRG2 in immune response was investigated. The association between PRRG2 expression and immune cell infiltration was also scrutinized. Ultimately, cellular and tissue identity were confirmed via immunohistochemical staining and quantitative real-time PCR.

Results: The study elucidates a notable decrease in PRRG2 expression in KIRC patients, correlating with demographic factors, metastasis, and pathological staging, and portending an unfavorable prognosis. Bioinformatic analyses underscore PRRG2's role in immune response, with its expression significantly tied to immune cell infiltration and marker expression.

Conclusion: PRRG2 may potentially impact prognosis in KIRC patients by regulating immune infiltration, thus rendering PRRG2 a promising candidate prognostic biomarker for KIRC-associated immune infiltration.

References

Kang M, Park K, Lee C, Lee M, Han S, Li L . Small activating RNA induced expression of VHL gene in renal cell carcinoma. Int J Biochem Cell Biol. 2018; 97:36-42. DOI: 10.1016/j.biocel.2018.02.002. View

Ning Z, Liu K, Xiong H . Roles of BTLA in Immunity and Immune Disorders. Front Immunol. 2021; 12:654960. PMC: 8043046. DOI: 10.3389/fimmu.2021.654960. View

Wang W, Huang J, Chen J . Angiomotin-like proteins associate with and negatively regulate YAP1. J Biol Chem. 2010; 286(6):4364-70. PMC: 3039387. DOI: 10.1074/jbc.C110.205401. View

Watt W, Cecil D, Disis M . Selection of epitopes from self-antigens for eliciting Th2 or Th1 activity in the treatment of autoimmune disease or cancer. Semin Immunopathol. 2016; 39(3):245-253. DOI: 10.1007/s00281-016-0596-7. View

Tekguc M, Wing J, Osaki M, Long J, Sakaguchi S . Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells. Proc Natl Acad Sci U S A. 2021; 118(30). PMC: 8325248. DOI: 10.1073/pnas.2023739118. View

Zhou Y, Zhang J, Li H, Huang T, Wong C, Wu F . AMOTL1 enhances YAP1 stability and promotes YAP1-driven gastric oncogenesis. Oncogene. 2020; 39(22):4375-4389. PMC: 7253359. DOI: 10.1038/s41388-020-1293-5. View

Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G . Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. 2011; 71(4):1263-71. DOI: 10.1158/0008-5472.CAN-10-2907. View

Kulman J, Harris J, Haldeman B, Davie E . Primary structure and tissue distribution of two novel proline-rich gamma-carboxyglutamic acid proteins. Proc Natl Acad Sci U S A. 1997; 94(17):9058-62. PMC: 23027. DOI: 10.1073/pnas.94.17.9058. View

Huang J, Wu S, Barrera J, Matthews K, Pan D . The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell. 2005; 122(3):421-34. DOI: 10.1016/j.cell.2005.06.007. View

10.

Yeo J, Ko M, Lee D, Park Y, Jin H . TIGIT/CD226 Axis Regulates Anti-Tumor Immunity. Pharmaceuticals (Basel). 2021; 14(3). PMC: 7997242. DOI: 10.3390/ph14030200. View

11.

Murphy T, Murphy K . Slow down and survive: Enigmatic immunoregulation by BTLA and HVEM. Annu Rev Immunol. 2010; 28:389-411. DOI: 10.1146/annurev-immunol-030409-101202. View

12.

Li Y, Guo J, Shen H, Li J, Yang N, Frangou C . Phosphorylation of Tyr188 in the WW domain of YAP1 plays an essential role in YAP1-induced cellular transformation. Cell Cycle. 2016; 15(18):2497-505. PMC: 5026814. DOI: 10.1080/15384101.2016.1207836. View

13.

Wang K, Ma F, Arai S, Wang Y, Varkaris A, Poluben L . WNT5a Signaling through ROR2 Activates the Hippo Pathway to Suppress YAP1 Activity and Tumor Growth. Cancer Res. 2023; 83(7):1016-1030. PMC: 10073315. DOI: 10.1158/0008-5472.CAN-22-3003. View

14.

Celano M, Mignogna C, Rosignolo F, Sponziello M, Iannone M, Lepore S . Expression of YAP1 in aggressive thyroid cancer. Endocrine. 2017; 59(1):209-212. DOI: 10.1007/s12020-017-1240-6. View

15.

Faber P, Barnes G, Srinidhi J, Chen J, Gusella J, Macdonald M . Huntingtin interacts with a family of WW domain proteins. Hum Mol Genet. 1998; 7(9):1463-74. DOI: 10.1093/hmg/7.9.1463. View

16.

Lai G, Zhong X, Liu H, Deng J, Li K, Xie B . Development of a Hallmark Pathway-Related Gene Signature Associated with Immune Response for Lower Grade Gliomas. Int J Mol Sci. 2022; 23(19). PMC: 9570050. DOI: 10.3390/ijms231911971. View

17.

Bylinska A, Wilczynska K, Malejczyk J, Milewski L, Wagner M, Jasek M . The impact of HLA-G, LILRB1 and LILRB2 gene polymorphisms on susceptibility to and severity of endometriosis. Mol Genet Genomics. 2017; 293(3):601-613. PMC: 5948266. DOI: 10.1007/s00438-017-1404-3. View

18.

Seton-Rogers S . Oncogenes: All eyes on YAP1. Nat Rev Cancer. 2014; 14(8):514-5. DOI: 10.1038/nrc3791. View

19.

Yazicioglu M, Monaldini L, Chu K, Khazi F, Murphy S, Huang H . Cellular localization and characterization of cytosolic binding partners for Gla domain-containing proteins PRRG4 and PRRG2. J Biol Chem. 2013; 288(36):25908-25914. PMC: 3764795. DOI: 10.1074/jbc.M113.484683. View

20.

Fan J, Wang L, Chen M, Zhang J, Li J, Song F . Analysis of the expression and prognosis for leukocyte immunoglobulin-like receptor subfamily B in human liver cancer. World J Surg Oncol. 2022; 20(1):92. PMC: 8943947. DOI: 10.1186/s12957-022-02562-w. View